MSD getting closer to USD 40bn acquisition of Seagen, media reports

The two companies are discussing a price of over USD 200 per share and a final agreement by July 28.

Photo: MSD / PR

US-based pharmaceutical giant MSD is in advanced negotiations concerning the acquisition of Seagen, a biotech firm focusing on oncology, for around USD 40bn, the Wall Street Journal reports after speaking to people close to the matter.

According to their sources, the estimated price will be over USD 200m per share and the deal is expected to be closed before the publication of Merck’s accounting report on July 28.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs